Lucy K. Shewell

Lucy K. Shewell

Auto-generated profile, based on publicly available information

Lucy K. Shewell

Institute for Glycomics, Griffith University, Gold Coast, Australia

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
LSLucy K. Shewell
Lucy K. Shewell
CDChristopher Day
Christopher Day
FJFreda E.-C. Jen
Freda E.-C. Jen
THThomas Haselhorst
Thomas Haselhorst
JAJohn Atack
John Atack
MJMichael Paul Jennings
Michael Paul Jennings
Cholesterol-dependent cytolysins (CDCs) form pores in cholesterol-rich membranes, but cholesterol alone is insufficient to explain their cell and host tropism. Here, we show that all eight major CDCs have high-affinity lectin activity that identifies glycans as candidate cellular receptors. Streptolysin O, vaginolysin, and perfringolysin O bind multiple glycans, while pneumolysin, lectinolysin, and listeriolysin O recognize a single glycan class. Addition of exogenous carbohydrate receptors for each CDC inhibits toxin activity. We present a structure for suilysin domain 4 in complex with two distinct glycan receptors, P1 antigen and αGal/Galili. We report a wide range of binding affinities for cholesterol and for the cholesterol analog pregnenolone sulfate and show that CDCs bind glycans and cholesterol independently. Intermedilysin binds to the sialyl-TF O-glycan on its erythrocyte receptor, CD59. Removing sialyl-TF from CD59 reduces intermedilysin binding. Glycan-lectin interactions underpin the cellular tropism of CDCs and provide molecular targets to block their cytotoxic activity.

5 January 2021 in Science Signaling
Verified
Journal Article
Closed access
BEBassam A Elgamoudi
Bassam A Elgamoudi
EAEkaterina P. Andrianova
Ekaterina P. Andrianova
LSLucy K. Shewell
Lucy K. Shewell
CDChristopher Day
Christopher Day
RKRebecca M. King
Rebecca M. King
Victoria KorolikVictoria Korolik
Victoria Korolik
Two ligand-binding sites in a chemoreceptor enable a human bacterial pathogen to adapt to hosts.

17 February 2023 in Translational Oncology
Verified
Journal Article
Open access
JWJing Wang
Jing Wang
LSLucy K. Shewell
Lucy K. Shewell
CDChristopher Day
Christopher Day
MJMichael Paul Jennings
Michael Paul Jennings
One of the forms of aberrant glycosylation in human tumors is the expression of N-glycolylneuraminic acid (Neu5Gc). The only known enzyme to biosynthesize Neu5Gc in mammals, cytidine-5'-monophosphate-N-acetylneuraminic acid (CMAH), appears to be genetically inactivated in humans. Regardless, low levels of Neu5Gc have been detected in healthy humans. Therefore, it is proposed that the presence of Neu5Gc in humans is from dietary acquisition, such as red meat. Notably, detection of elevated Neu5Gc levels has been repeatedly found in cancer tissues, cells and serum samples, thereby Neu5Gc-containing antigens may be exploited as a class of cancer biomarkers. Here we review the findings to date on using Neu5Gc-containing tumor glycoconjugates as a class of cancer biomarkers for cancer detection, surveillance, prognosis and therapeutic targets. We review the evidence that supports an emerging hypothesis of de novo Neu5Gc biosynthesis in human cancer cells as a source of Neu5Gc in human tumors, generated under certain metabolic conditions.

20 December 2022 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Open access
LSLucy K. Shewell
Lucy K. Shewell
CDChristopher Day
Christopher Day
THTiana Hippolite
Tiana Hippolite
XBXavier De Bisscop
Xavier De Bisscop
JPJames C. Paton
James C. Paton
MJMichael Paul Jennings
Michael Paul Jennings
Cutaneous melanoma is one of the most aggressive and deadly types of skin cancer and rates of disease are continuing to increase worldwide. Currently, no serum biomarkers exist for the early detection of cutaneous melanoma. Normal human cells cannot make the sialic acid sugar, Neu5Gc, yet human tumor cells express Neu5Gc and Neu5Gc-containing glycoconjugates have been proposed as tumor biomarkers. We engineered a Neu5Gc-specific lectin based on the pentameric B-subunit of the Shiga toxigenic Escherichia coli subtilase cytotoxin, termed SubB2M. We have detected elevated Neu5Gc-containing biomarkers in the sera of ovarian and breast cancer patients in a highly sensitive surface plasmon resonance (SPR)-based assay using our SubB2M lectin. Here, we used the SubB2M-SPR assay to investigate Neu5Gc-containing glycoconjugates in the serum of cutaneous melanoma patients. We found elevated total serum Neu5Gc levels in primary (n = 24) and metastatic (n = 38) patients compared to cancer-free controls (n = 34). Serum Neu5Gc levels detected with SubB2M can distinguish cutaneous melanoma patients from cancer-free controls with high sensitivity and specificity as determined by ROC curve analysis. These data indicate that serum Neu5Gc-containing glycoconjugates are a novel class of biomarkers for cutaneous melanoma, particularly for primary melanoma, and have the potential to contribute to the early diagnosis of this disease.